Perimeter Medical Imaging AI Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update
08 Noviembre 2022 - 4:01PM
Business Wire
Hosting Call on Tuesday, November 15th at 5
pm ET
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF)
(FSE: 4PC) (“Perimeter” or the “Company”) – a medical technology
company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
high unmet medical needs – today announced it will report its third
quarter 2022 financial and operating results after the close of
U.S. financial markets on Tuesday, November 15, 2022.
Conference
Call/Webcast Information:
Date:
Tuesday, November 15, 2022
Time:
5:00 pm Eastern Time
Dial-In Number:
1-877-704-4453
International Dial-In:
1-201-389-0920
Conference ID:
13734184
Presenters:
Jeremy Sobotta, Chief Executive
Officer
Chris Scott, Chief Financial
Officer
The call will also be broadcast live online through a
listen-only webcast, which will be posted on the Investors section
of the Company's website. The webcast will be archived on the
Company's investor relations webpage for at least 90 days. A
telephonic playback of the conference call will be available for 14
days after the conference call by calling 1-844-512-2921 or
1-412-317-6671 from abroad and referencing conference ID 13734184.
The above listed dates and times are subject to change.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical
technology company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
areas of high unmet medical need. Available across the U.S., our
FDA-cleared Perimeter S-Series OCT system provides real-time,
cross-sectional visualization of excised tissues at the cellular
level, with 10x greater image resolution than X-ray and ultrasound,
and 100x greater than MRI. The breakthrough-device-designated
investigational Perimeter B-Series OCT with ImgAssist AI represents
our next-generation artificial intelligence technology that is
currently being evaluated in a pivotal clinical trial, with support
from a grant of up to US$7.4 million awarded by the Cancer
Prevention and Research Institute of Texas. The company’s ticker
symbol “PINK” is a reference to the pink ribbons displayed during
Breast Cancer Awareness Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains statements that constitute
“forward-looking information” within the meaning of applicable
Canadian securities legislation. In this news release, words such
as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,”
“anticipate,” “intend,” “plan,” “estimate,” and similar words and
the negative form thereof are used to identify forward-looking
statements. Forward-looking information may relate to management’s
future outlook and anticipated events or results and may include
statements or information regarding the future financial position,
business strategy and strategic goals, competitive conditions,
research and development activities, projected costs and capital
expenditures, research and clinical testing outcomes, taxes and
plans and objectives of, or involving, Perimeter. Without
limitation, information regarding the potential benefits of
Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter
ImgAssist are forward-looking information. Forward-looking
statements should not be read as guarantees of future performance
or results, and will not necessarily be accurate indications of
whether, or the times at or by which, any particular result will be
achieved. No assurance can be given that any events anticipated by
the forward-looking information will transpire or occur.
Forward-looking information is based on information available at
the time and/or management’s good-faith belief with respect to
future events and are subject to known or unknown risks,
uncertainties, assumptions, and other unpredictable factors, many
of which are beyond Perimeter’s control. Such forward-looking
statements reflect Perimeter’s current view with respect to future
events, but are inherently subject to significant medical,
scientific, business, economic, competitive, political, and social
uncertainties and contingencies. In making forward-looking
statements, Perimeter may make various material assumptions,
including but not limited to (i) the accuracy of Perimeter’s
financial projections; (ii) obtaining positive results from trials;
(iii) obtaining necessary regulatory approvals; and (iv) general
business, market, and economic conditions. Further risks,
uncertainties and assumptions include, but are not limited to,
those applicable to Perimeter and described in Perimeter’s
Management Discussion and Analysis for the year ended December 31,
2021, which is available on Perimeter’s SEDAR profile at
www.sedar.com, and could cause actual events or results to differ
materially from those projected in any forward-looking statements.
Perimeter does not intend, nor does Perimeter undertake any
obligation, to update or revise any forward-looking information
contained in this news release to reflect subsequent information,
events, or circumstances or otherwise, except if required by
applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221108005956/en/
Jodi Regts Perimeter Medical Imaging AI, Inc. Direct:
469-743-1834 Toll-free: 888-988-7465 (PINK) Investors:
investors@perimetermed.com Media: media@perimetermed.com
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Mar 2025 a Abr 2025
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Abr 2024 a Abr 2025